MENU

Are these the next ASX biotech stars?

All the way back in 2003 CSL Limited (ASX: CSL) shares were changing hands at under $12.00.

Fifteen years later those same shares have increased in value by over 1,200% and recently traded as high as $159.62.

While only time will tell whether the biotech shares listed below can have similar success, I think they are well worth keeping a close eye on.

Botanix Pharmaceuticals Ltd (ASX: BOT)

In February this dermatology company raised $15 million through a placement of shares at an issue price of 11 cents per share. The funds raised are to be used to accelerate clinical development of its lead acne product, BTX 1503, and progress other key pipeline products. I think BTX 1503 is a very exciting product and have been impressed with its early results. It uses a synthetic cannabidiol to treat moderate to severe acne and, importantly, does not come with the horrific side effects that existing products have. The acne prescription market is expected to be worth up to US$4.5 billion this year, meaning this drug could have significant potential if its trials are a success.

Cynata Therapeutics Ltd (ASX: CYP)

Through its impressive Cymerus technology, Cynata Therapeutics is able to produce an unlimited number of high quality and consistent stem cells at a low cost. These stem cells can then be used to treat a number of diseases including Graft versus Host Disease (GvHD) through it lead CYP-001 mesenchymal stem cell (MSC) product. The market opportunity for this treatment alone is estimated to be US$300 million a year. Pleasingly, the company advised recently that CYP-001 has been granted Orphan Drug Designation by the United Stated Food and Drug Administration.

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals. Its CEO, Dr Christian Behrenbruch, is very respected in the industry and has a solid track record of success in the field. This morning the company advised that its joint venture with Kyzeo Imaging has entered into a material contract with US-listed Endocyte in relation to providing imaging technology for Endocyte’s phase III trial of Lu-PSMA-617. This is just one of a number of positive developments ongoing or in the pipeline, making it one to watch in my opinion.

The Disruptors: 3 More Exciting Aussie Companies to Watch

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor James Mickleboro owns shares of TELIXPHARM DEF SET. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The 5 mining stocks we’re recommending in 2019…

For decades, Australian mining companies have minted money for individual investors like you and me. But if you believe the pundits and talking heads on TV, those days are long gone. Finito! Behind us forever…

We say nothing could be further from the truth. To earn the really massive returns, you’ve got to fish where others aren’t fishing—and the mining sector could be primed for a resurgence. That’s why top Motley Fool analysts just revealed their exciting new research on 5 ASX miners they believe could help you profit in 2019 and beyond…

Including:

The best way we see to play the global zinc shortage… Our #1 favourite large-cap miner (hint: it’s not BHP)… one early-stage gold miner we think could hit the motherlode… Plus two more surprising companies you probably haven’t heard of yet!

For free access to our brand-new research, simply click here or the link below. But be warned, this research is available free for a limited time only, and we reserve the right to withdraw it at any time.

Click here for your FREE report!